Recent Headlines
AdvantaPure(R) Invests in Training Its Team Members; Partners with Worcester Polytechnic Institute for Biomanufacturing Training
Employees from AdvantaPure, a manufacturer of high purity tubing and Single-Use components for biopharma manufacturing, recently received customized training at the Biomanufacturing Education and Training Center of Worcester Polytechnic Institute in Worcester, Mass. The training involved classroom and hands-on instruction to teach the employees about the equipment and processes used by their customers in their pharmaceutical and biopharmaceutical manufacturing operations. - February 07, 2015 - AdvantaPure
Local Pharmacy Wants to Warm Those Less Fortunate
Country Village Chemists of Huntington Asks the Public to Support Their Annual Winter Coat Drive. - February 06, 2015 - North Country Drugs
HiLyte™ Your Antibodies Using One Universal Reagent
AnaSpec is pleased to announce the release of a product line of recombinant Protein A, conjugated with HiLyte™ Fluor dyes or Biotin. This universal reagent can be used to detect antibodies from different species, such as human, rabbit, mouse, rat and others. Protein A is available as labeled... - January 30, 2015 - AnaSpec, EGT Group
Boston Healthcare Appoints Andreas H. Sander as Vice President and Managing Director of Boston Healthcare International GmbH
Boston Healthcare today announced the appointment of Andreas Sander as Vice President and Managing Director for Boston Healthcare International GmbH, leading the European team and the firm’s activities in Germany and Europe out of Boston Healthcare’s Berlin office. Mr. Sander brings... - January 21, 2015 - Boston Healthcare
Braasch Biotech Bolsters Intellectual Property with Patent Acceptance in the Philippines
Braasch Biotech LLC continues patent portfolio expansion with new issue in the Philippines. Novel technologies allow safe enhancement of livestock productivity by use of vaccination rather than exogenous pharmaceuticals. - January 15, 2015 - Braasch Biotech LLC
AveXis Closes Its Series C Financing Round with Deerfield Management and Roche Venture Fund
AveXis, Inc., a biotechnology company focused on using gene therapy to transform the lives of patients with severe genetic and orphan diseases like Spinal Muscular Atrophy (SMA), today announced it has completed a $10 million financing round led by Deerfield Management and Roche Venture Fund. In... - January 08, 2015 - AveXis Inc.
Good News - Creative Biomart Newly Introduced Fucose-Free Protein Expression System
Creative Biomart, a world leading biotech company that specializes in providing advanced tolls for protein expression and purification, today has officially announced its release of novel service--Fucose-free Protein Expression System. According to its official speaker, this service is supported by... - January 07, 2015 - Creative Biomart
Creative Biomart Launches Special Promotion for Christmas and New Year
Creative Biomart, a world leading biotech company that provides recombinant proteins, enzymes and other quality products and services for customers all over the world, has announced today that they would launch a special promotion for Christmas and New year in this very day. According to its... - December 25, 2014 - Creative Biomart
Creative Biomart Newly Introduced Multiplex Protein Detect Assay
Creative Biomart, a world leading biotech company and the commitment of which is to improving people’s life by assisting scientists with their research, has announced today for its official release of Multiplex Protein Detect Assay Service. This release was said to provide better protein... - December 21, 2014 - Creative Biomart
Clinical and Economic Impact of Next-Generation Sequencing Examined During Boston Healthcare’s Multi-Stakeholder Symposium
Boston Healthcare Associates, Inc. (BHA) and Cambridge Healthtech Institute (CHI) held an engaging, multi-stakeholder symposium surrounding the unique challenges and opportunities with the use of next-generation sequencing (NGS) in oncology care. Entitled, “Capturing the Value of... - December 12, 2014 - Boston Healthcare
AveXis Announces Dosing of First Patient in Intermediate Cohort in Gene Transfer Trial
AveXis, Inc., a biotechnology company focused on using gene therapy to transform the lives of patients with severe genetic and orphan diseases like Spinal Muscular Atrophy (SMA), today announced that the first patient in the intermediate cohort in the Gene Transfer Clinical Trial for SMA Type 1 has... - December 10, 2014 - AveXis Inc.
AveXis Announces Launch of New Patient-Oriented Website Focused on Spinal Muscular Atrophy
AveXis, Inc., a biotechnology company focused on using gene therapy to transform the lives of patients with severe genetic and orphan diseases like Spinal Muscular Atrophy (SMA), is pleased to announce the launch of the company’s brand new website specifically focused on SMA: www.smastudy.org. - December 04, 2014 - AveXis Inc.
Creative Biomart’s Most-Favored Services List is Available Now
Creative Biomart, a world leading biotech company that offers recombinant proteins, antibodies, antigens and a wide range of biotech services worldwide, today has released its most favored services list officially. It was said that this was done to make them have a better understanding of what... - November 22, 2014 - Creative Biomart
AveXis to Present at the 26th Annual Piper Jaffray Healthcare Conference
AveXis, a biotechnology company focused on using gene therapy to transform the lives of patients with severe genetic and orphan diseases like Spinal Muscular Atrophy, today announced that Mr. John Carbona, Chief Executive Officer, and Dr. Brian Kaspar will present at the 26th Annual Piper Jaffray... - November 21, 2014 - AveXis Inc.
Patent Awarded to AdvantaPure(R)’s AdvantaPass(TM) Clean Room Wall Pass-Through System; Ensures Room Isolation During Fluid Transfer
A United States patent has been awarded to AdvantaPass, a clean room wall pass-through system designed to transfer fluids between clean rooms during pharmaceutical and biopharmaceutical production. The system is the first of its kind to provide complete isolation between manufacturing suites when transferring multiple fluid lines through a single wall portal. AdvantaPass uses Single-Use components, such as tubing and seals, along with durable stainless steel in-wall parts. - November 20, 2014 - AdvantaPure
Enzyme Activity Assay Service Are Available in Creative Biomart
Creative Biomart, a world leading supplier of recombinant proteins, antibodies, enzymes and other biotech services for the research community in the field of biology, has announced today for its official release of the novel service-- Enzyme activity assay. This assay is in the aim of assisting... - November 06, 2014 - Creative Biomart
OutsourcePharma Advisory Board CRO Reviews Database Surpasses Growth Milestone
Online community of outsourcing decision makers doubles its CRO reviews database - October 15, 2014 - Life Science Strategy Group, LLC
Creative Biomart Newly Introduced It’s Fc Fusion Protein Production Service
Creative Biomart, a word leading Biotech Company had newly released its novel service of Fc Fusion Protein Production Service in the aim of providing more choices for the scientists conducting biomedical and immunology research. The potential clinical application of cytokins to modulate immune... - October 10, 2014 - Creative Biomart
AveXis Announces the Completion of Dosing of the Low Dose Cohort in US Clinical Trial for Spinal Muscular Atrophy
AveXis, Inc., a clinic-stage gene therapy company, today announced the completion of dosing in the low dose cohort in the world's first human gene therapy trial for the treatment of infants with spinal muscular atrophy (SMA). The trial (NCT02122952) opened for enrollment in April... - October 08, 2014 - AveXis Inc.
FDAnews Announces: FDA Official Added to 9th Annual FDA Inspections Summit, Oct. 22-24, 2014
9th Annual FDA Inspections Summit Presented by FDAnews; Oct. 22-24, 2014 – Bethesda, MD; www.fdanews.com/InspectionsSummitPR2 - October 05, 2014 - FDAnews
AveXis Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for chariSMA for the Treatment of Spinal Muscular Atrophy
AveXis Inc., a synthetic biology platform company primarily focused on developing treatments for Spinal Muscular Atrophy (SMA) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its product scAAV9, called chariSMA to treat Spinal Muscular Atrophy... - October 04, 2014 - AveXis Inc.
Creative Biomart Morning Talk for Mutagenesis Services
Creative BioMart, a world leading Biotech Company, has conducted a morning talk to discuss its mutagenesis. This talk lasted for nearly one hour. Mutagenesis is a fundamentally important DNA manipulation technique. It involves changing the base sequence of the DNA molecule, usually for the... - September 18, 2014 - Creative Biomart
CarpeVITA Natural Products Has Announced It is the Now Exclusive US Distributor of Erba Vita, the Leading Herbal Supplement Brand in Italy
CarpeVITA Natural Products has announced it is the now exclusive US distributor of Erba Vita, the leading herbal supplement brand in Italy and one of Europe's leading brands. All supplements are non-GMO & produced with the highest European standards. - September 15, 2014 - CarpeVITA Natural Products
Creative Biomart Newly Introduced Its Stable Cell Line Service
Creative Biomart today has given an announcement that they would release their new service-stable cell line service in this very day to meet their customer’s need. Stable cell lines are essential for protein and antibody and cell-based assays. But the processes required for the generation of... - September 11, 2014 - Creative Biomart
Creative Biomart Newly Released a Bunch of Over-Expression Lysates
Official marketing staff of Creative Biomart has announced today of their new products release for over-expression lysates. According to its official announcement, this new release is mainly an enhancement of their lysates product. Nearly 9,000 of products have been added in this launch such as... - September 02, 2014 - Creative Biomart
Creative Biomart Introduced Immobilized Enzyme Service
On August 24, 2014, Creative Biomart has introduced their novel service of immobilized enzymes. This novel service is based on a revolutionary new platform, combining affinity tag binding with inert porous materials, designed especially for biocatalysis application in any organic solvent or... - August 27, 2014 - Creative Biomart
Braasch Biotech to Participate at Informa's 9th Annual Veterinary Vaccine Conference
Braasch's Biotech's Dr. Keith Haffer to host seminar on adjuvants at Informa's Veterinary Vaccine Conference in December. - August 25, 2014 - Braasch Biotech LLC
Cheers—Creative Biomart Launches High-Throughput Protein Production
The marketing chief staff of Creative Biomart has announced today that they will release the high-throughput protein production service on this very day in the aim of helping speed up their customer’s protein production project. Protein expression is widely used in the production of... - August 22, 2014 - Creative Biomart
Creative Biomart Launches Novel Service for Protein Labeling
On August 18, Creative Biomart had launched a novel service that is site-specific and custom labeling for protein labeling. This new service includes C-terminal labeling, N-terminal labeling, and Labeling at glycosylation sites. The launch of the site-specific and custom labeling service was said... - August 22, 2014 - Creative Biomart
Creative Biomart Signed Industrial Enzymes Agreement
Creative Biomart signed an Industrial Enzymes Agreement with a UK Industrial giant (the name of the company is not allowed to be exposed according to the agreement). On the basis of this agreement, Creative Biomart is going to provide High-temperature Alpha-amylase for beer, Mid-temperature... - August 20, 2014 - Creative Biomart
AveXis Announces Dosing of First Patient for Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 at Nationwide Children’s Hospital
AveXis, Inc., a synthetic biology platform company, today announced that the first patient in the Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 has now been enrolled and dosed by Nationwide Children’s Hospital. This trial utilizes chariSMA, the gene therapy product developed... - June 26, 2014 - AveXis Inc.
iPathwayGuide Now Available in Illumina’s BaseSpace Apps
Advaita Bioinformatics today announced the addition of its iPathwayGuide application to BaseSpace Apps, Illumina’s applications store and informatics community dedicated to advancing genomic analysis. iPathwayGuide is a web based pathway analysis tool that goes beyond the typical statistical... - June 25, 2014 - Advaita Corporation
UCR (Uppsala Clinical Research Center) Selected Ethical eAdjudication® to Support the Clinical Endpoints Adjudication Process
Uppsala Clinical Research Center (UCR), a top Academic Research Organization based in Sweden, adopted Ethical eAdjudication® cloud-based platform to manage the central assessment of Clinical Trial Endpoints by an independent CEC (Clinical Endpoint Classification) Committee. - June 21, 2014 - Ethical GmbH
AveXis to Present at Piper Jaffray GenomeRX Symposium
AveXis, a clinical stage synthetic biology platform company, today announced that Mr. John Carbona, Chief Executive Officer and other members of the AveXis team will participate in the panel discussion “The Power Alley: Gene Therapy For Neuromuscular Disorders” at the Piper Jaffray... - June 20, 2014 - AveXis Inc.
Discover the Next IDE Inhibitor with the Newly Launched SensoLyte® IDE Activity Assay
AnaSpec Launches Industry’s First FRET-based Assay for Measurement of Insulin Degrading Enzyme (IDE) Activity for inhibitor high throughput screening- the SensoLyte® 520 IDE Activity Assay Kit. - June 12, 2014 - AnaSpec, EGT Group
AveXis to Present at Families of Spinal Muscular Atrophy Annual Conference
AveXis, a clinical stage synthetic biology platform company, today announced that Dr. Allan Kaspar, Chief Scientific Officer, will be presenting at The Family and Researcher Poster Session at The Annual Spinal Muscular Atrophy Conference, which will be held on Thursday, June 12, 2014 in National... - June 08, 2014 - AveXis Inc.
Industry's First Fluorimetric Assay for Glutaminyl Cyclase
AnaSpec Launches Industry’s First Fluorimetric, 96-well format Assay for Measurement of Glutaminyl Cyclase (QC) Activity - the SensoLyte® Green Glutaminyl Cyclase Activity Assay Kit. - May 29, 2014 - AnaSpec, EGT Group
Life Science Strategy Group Launches the OutsourcePharma Advisory Board
Online community dedicated to pharmaceutical sponsors provides open forum to discuss drug development and outsourced Contract Research Organization (CRO) services. - May 28, 2014 - Life Science Strategy Group, LLC
AveXis Announces Opening of Enrollment for Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 at Nationwide Children's Hospital
AveXis, Inc., a clinic-ready synthetic biology platform company, today announced that the Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 has now formally begun enrollment at Nationwide Children’s Hospital. This trial will utilize chariSMA, the gene therapy product developed... - May 16, 2014 - AveXis Inc.
BiologicsCorp Launches Supernatant Protein Expression Service
BiologicsCorp proudly launches this new service - another first in the industry. They have tested many variables, including codon optimization, strain, charperones and foldases, and others. Give Supernatant Service a try, especially if your protein of interest could not be expressed in soluble form. BiologicsCorp is confident and can guarantee success - no soluble fraction for target protein, no payment for expression service. - April 25, 2014 - BiologicsCorp
AveXis Closes a Round of Financing from PBM Capital to Advance Its SMA Gene Therapy Program
AveXis, Inc., a clinic-ready synthetic biology platform company, today announced it has completed a financing round led by PBM Capital Group. This round of financing will help support the company’s gene therapy program targeting spinal muscular atrophy (SMA). AveXis’ gene therapy... - April 23, 2014 - AveXis Inc.
Dr. Kristy Ainslie Strengthens Drug Delivery Focus as She Becomes Advisor to Peptineo
Peptineo is pleased to welcome Dr. Ainslie to advisory board at Peptineo. Dr. Ainslie received her PhD in Chemical Engineering from Penn State, and after a short post doc in a start up company focused on biosensor development, Protiveris, she completed a post doc at UCSF. During her post doc, she... - April 08, 2014 - Peptineo
Dr. Applegate to Join Advisory Board at Peptineo
Peptineo is pleased to welcome Dr. Robert Applegate to the advisory board of Peptineo. Dr. Applegate is a recognized expert in microfluidics, biomedical devices and optical technologies. As a result of his research, Dr. Applegate holds patents in optical trapping, cell diagnostics and sorting, and... - April 07, 2014 - Peptineo
Peptineo, a Biotechnology Company Focused on Value Recovery in Pharma, Announces the Appointment of Kamal Garcha PhD., to Advisory Board
"We welcome the addition of Dr. Garcha," noted Sheldon K. Jordan, PhD, CEO. Dr. Garcha holds an Honor’s BSC in Cell Biology and MSc. in Zoology from Western University, and a PhD. in Cellular & Physiological Sciences from the University of British Columbia. During the course of... - April 02, 2014 - Peptineo
OsoBio Appoints Catherine Buck Director of Manufacturing
Buck has 20-plus years of experience managing pharma and commercial manufacturing plants. - April 02, 2014 - OSO BioPharmaceuticals Manufacturing, LLC
Peptineo Adds Dr. Yoganathan to Advisory Board to Strengthen Biomaterials Development and Commercialization
Dr. Yoganathan is a SME in the areas of biomaterials and drug delivery - having collaborated and worked closely with thought-leaders in the field such as Dr. Robert Langer, Dr. Kazunori Kataoka, Dr. Michael V. Sefton and Dr. Christine Allen. He is an expert in manipulating material properties to... - March 31, 2014 - Peptineo
Peptineo Announces Appointment of David M. Wyatt to Advisory Board
Peptineo is pleased to announce the appointment of David M. Wyatt to their advisory board. David has had over 25 years of technical and business experience in the development of controlled release pharmaceutical products. He has held senior management positions in sales and business development,... - March 27, 2014 - Peptineo
Dr. Sundar Nadarajan Joins the Advisory Board at Peptineo to Guide Nanotechnology Drug Delivery Platform for Protein Therapeutics
Sheldon K. Jordan, PhD, President and CEO, Peptineo, announces the appointment of Sundar Nadarajan, PhD, to the company's Scientific Advisory Board. They are extremely pleased that Dr. Nadarajan has joined the Peptineo Scientific Advisory Board. "He is an accomplished scientist and consulting... - March 27, 2014 - Peptineo
Creative Biomart Launches New Services: Protein Labeling & Conjugation
Creative Biomart has announced the launch of a new offering for protein labeling and conjugation. - March 13, 2014 - Creative Biomart
AnaSpec Now Offers 5-Hydroxymethyl Cytosine Monoclonal Antibody (Clone 4D9)
A mouse monoclonal antibody specifically recognizing 5-hydroxymethyl Cytosine (5-hmC) is now available from AnaSpec. - February 21, 2014 - AnaSpec, EGT Group